Martin Aispuro Pablo, Ambrosis Nicolás, Zurita María Eugenia, Gaillard María Emilia, Bottero Daniela, Hozbor Daniela Flavia
Laboratorio VacSal, Instituto de Biotecnología y Biología Molecular (IBBM), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Centro Científico Tecnológico - Consejo Nacional de Investigaciones Científicas y Técnicas (CCT-CONICET), La Plata, Argentina.
Front Microbiol. 2020 Apr 17;11:723. doi: 10.3389/fmicb.2020.00723. eCollection 2020.
Newborns and unvaccinated infants, compared to other age groups, are more susceptible to pertussis infection, manifesting severe symptoms leading to a higher mortality. The recent increase in pertussis cases demands more effective strategies to overcome this major health problem. In parallel with maternal-immunization, neonatal-immunization (NI) is a strategy needing revision. Here, using the intranasal-challenge-mouse-model we evaluated the protective capacity of NI in both naïve-mice and those with maternally acquired immunity. We tested our acellular-vaccine-candidate based on outer-membrane-vesicles derived from (OMVP) that induces Th2-profile but also the recommended Th-profile for protection: Th1/Th17-profile and CD4 T-memory-cells that reside in the lungs. Commercial acellular-vaccine (aP) and whole cell-vaccine (wP) inducing mainly Th2-profile and Th1-profile, respectively, were also tested. Analyzing the induced immunity and protection capability of NI included in 1- or 2-dose schedules with the same or different types of vaccine, we detected that the aP-vaccine administered in either single- or 2-dose schedules protected against sublethal infection. Schedules consisting of doses of aP neonatally and of OMVP or wP vaccine during infancy greatly reduced bacterial lung colonization while inducing the highest levels of high-avidity anti-pertussis toxin (PTx) IgG. That OMVP or wP neonatal dose did not interfere with the protection of transferred maternal immunity was especially encouraging. Moreover, OMVP- or wP used as a neonatal dose enhanced the quality of the humoral immune response in immunized pups. Antibodies generated by OMVP-or wP-vaccinated mice born to aP-immunized mothers were of higher avidity than those from mice that harbored only maternal immunity; but when mothers and neonates were immunized with the same aP-vaccine, the humoral response in the neonates was partially suppressed through the blunting of the level of anti-PTx IgG induced by the neonatal aP dose. These results demonstrated that neonatal immunization is a possible strategy to be considered to improve the current pertussis epidemiology. For neonates without maternal-immunity, mixed-vaccination schedules that include the aP- and OMVP-vaccines appear to be the most appropriate to induce protection in the pups. For offspring from immune mothers, to avoid blunting-effect, NI should be carried out with vaccines other than those applied during pregnancy.
与其他年龄组相比,新生儿和未接种疫苗的婴儿更容易感染百日咳,表现出严重症状,导致更高的死亡率。近期百日咳病例的增加需要更有效的策略来克服这一重大健康问题。与母体免疫并行,新生儿免疫(NI)是一种需要修订的策略。在此,我们使用鼻内攻击小鼠模型评估了NI在未接触过抗原的小鼠和具有母体获得性免疫的小鼠中的保护能力。我们测试了基于源自(OMVP)的外膜囊泡的无细胞候选疫苗,该疫苗诱导Th2型免疫反应,但也是推荐的用于保护的Th型免疫反应:Th1/Th17型免疫反应以及驻留在肺部的CD4 T记忆细胞。还测试了分别主要诱导Th2型和Th1型免疫反应的商业无细胞疫苗(aP)和全细胞疫苗(wP)。通过分析1剂或2剂接种方案、使用相同或不同类型疫苗的NI诱导的免疫和保护能力,我们发现单剂量或2剂量接种方案的aP疫苗可预防亚致死性感染。由新生儿期接种aP疫苗以及婴儿期接种OMVP或wP疫苗组成的接种方案可大大减少细菌在肺部的定植,同时诱导产生最高水平的高亲和力抗百日咳毒素(PTx)IgG。OMVP或wP新生儿剂量不会干扰转移的母体免疫的保护作用,这一点尤其令人鼓舞。此外,用作新生儿剂量的OMVP或wP可提高免疫幼崽体液免疫反应的质量。由aP免疫的母亲所生、接种OMVP或wP疫苗的小鼠产生的抗体亲和力高于仅具有母体免疫的小鼠产生的抗体;但是当母亲和新生儿接种相同的aP疫苗时,新生儿期aP剂量诱导的抗PTx IgG水平降低,从而部分抑制了新生儿的体液反应。这些结果表明,新生儿免疫是改善当前百日咳流行情况可考虑的一种策略。对于没有母体免疫的新生儿,包括aP和OMVP疫苗的混合接种方案似乎最适合在幼崽中诱导保护作用。对于免疫母亲的后代,为避免钝化效应,NI应使用与孕期接种的疫苗不同的疫苗进行。